Clinical Trials Browser

Nasopharyngeal Carcinoma

Rectal Neoplasms

Endometrial Neoplasms

Colonic Neoplasms

Neoplasm Metastasis

Carcinoma, Hepatocellular

Neoplasms, Unknown Primary

Colorectal Neoplasms

Pancreatic Neoplasms

Triple Negative Breast Neoplasms

Carcinoma, Hepatocellular

Triple Negative Breast Neoplasms

Cholangiocarcinoma

Carcinoma, Non-Small-Cell Lung

Esophageal Neoplasms

Appendiceal Neoplasms, Neoplasm Metastasis

Lung Squamous Cell Carcinoma

Carcinoma, Hepatocellular

Gastric Adenocarcinoma

Carcinoma, Hepatocellular

Breast Neoplasms

Locally Advanced Rectal Cancer

Uterine Cervical Neoplasms, Esophageal Neoplasms, Endometrial Neoplasms

Stomach Neoplasms

Stomach Neoplasms

Uterine Cervical Neoplasms

Rectal Neoplasms

Carcinoma, Non-Small-Cell Lung

Pancreatic Neoplasms

Hemangiosarcoma

Advanced Solid Tumors

Stomach Neoplasms

Carcinoma, Hepatocellular

Pancreatic Neoplasms

Carcinoma, Hepatocellular, Recurrence

Metastatic Gastroesophageal Junction Adenocarcinoma

Advanced Digestive System Tumor

Carcinoma, Non-Small-Cell Lung

Colorectal Neoplasms

Locally Advanced Rectal Cancer (LARC)

Adenocarcinoma, Stomach Neoplasms

Stomach Neoplasms

Neuroblastoma

Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

Neoplasms, Stomach Neoplasms

Thyroid Neoplasms

Colorectal Cancer Metastatic

Stomach Neoplasms

Clinical Trials

Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC

SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC

FEMUS

TRIUNITE-08

Study of ABO2102 in KRAS-Mutated Solid Tumors

A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)

Sintilimab in Cancer of Unknown Primary

Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer

XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer

Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.

Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)

Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)

HAIC Combined With Donafenib and Sintilimab for Unresectable ICC

SACTION 2501

ESO-Nanjing7

Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma

Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung Cancer

Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma

ARTEMIS-GC3

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors

CISN-L

NLCCRIT-LARC

Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1

Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric Cancer

Remission

Clinical Study to Evaluate the Efficacy and Safety of Nab-Paclitaxel Combined With Cisplatin and Sintilimab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer

A Single-Center, Single-Arm Study of Neoadjuvant Short-Course Radiotherapy With IL-2 Followed by Sequential Immunotherapy With CAPOX Combined With PD-1 Antibody and IL-2 for Locally Advanced Rectal Cancer

A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer

Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer

Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study

Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0348 in Advanced Solid Tumors

A Benefit Population Atlas of nICT Versus nCT for LAGC

Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial

Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer

Adjuvant Sintilimab Plus Lenvatinib for HCC Characterized With VETC Following Liver Resection

Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer

CCGLC-018

Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer

Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases

STELLARIII

NeoRacing

IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer

Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma

Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients

PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)

YOUNG-NEOS

Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study

Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies）

Efficacy and Safety of Fruquintinib Combined With Sintilimab and Stereotactic Body Radiation Therapy (SBRT) for the Second-line and Higher-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Oligometastatic Progression